{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:29:36Z","timestamp":1791836976270,"version":"4.3.4"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1093\/neuonc\/nou148","type":"journal-article","created":{"date-parts":[[2014,8,7]],"date-time":"2014-08-07T01:32:55Z","timestamp":1407375175000},"page":"116-121","source":"Crossref","is-referenced-by-count":259,"title":["Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma"],"prefix":"10.1093","volume":"17","author":[{"given":"Thomas J.","family":"Kaley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Ligon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Haidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasan","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Lassman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig P.","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"DeAngelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Gavrilovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Norden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Drappatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eudocia Quant","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Purow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Plotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Batchelor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Abrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Omuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,8,6]]},"reference":[{"issue":"Suppl 2","key":"key\n\t\t\t\t20170511102401_NOU148C1","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/neuonc\/not151","article-title":"CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006\u20132010","volume":"15","author":"Ostrom","year":"2013","journal-title":"Neuro-oncology"},{"issue":"3","key":"key\n\t\t\t\t20170511102401_NOU148C2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11060-010-0349-8","article-title":"Medical therapies for meningiomas","volume":"99","author":"Wen","year":"2010","journal-title":"J Neurooncol"},{"issue":"2","key":"key\n\t\t\t\t20170511102401_NOU148C3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-011-0741-z","article-title":"Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma","volume":"107","author":"Chamberlain","year":"2012","journal-title":"J Neurooncol"},{"issue":"7","key":"key\n\t\t\t\t20170511102401_NOU148C4","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1212\/01.WNL.0000118300.82017.F4","article-title":"Temozolomide for treatment-resistant recurrent meningioma","volume":"62","author":"Chamberlain","year":"2004","journal-title":"Neurology"},{"issue":"3","key":"key\n\t\t\t\t20170511102401_NOU148C5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-005-9093-x","article-title":"Salvage chemotherapy with CPT-11 for recurrent meningioma","volume":"78","author":"Chamberlain","year":"2006","journal-title":"J Neurooncol"},{"key":"key\n\t\t\t\t20170511102401_NOU148C6","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2009.27.15_suppl.2063","article-title":"Southwest Oncology Group S9811: a phase II study of hydroxyurea for unresectable meningioma (abstract #2063)","volume":"27","author":"Swinnen","year":"2009","journal-title":"J Clin Oncol."},{"key":"key\n\t\t\t\t20170511102401_NOU148C7","first-page":"56a","article-title":"Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma","volume":"20","author":"Grunberg","year":"2001","journal-title":"Proc Am Soc Clinical Oncol."},{"issue":"1","key":"key\n\t\t\t\t20170511102401_NOU148C8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01050266","article-title":"A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study","volume":"15","author":"Goodwin","year":"1993","journal-title":"J Neurooncol"},{"issue":"6","key":"key\n\t\t\t\t20170511102401_NOU148C9","doi-asserted-by":"crossref","first-page":"861","DOI":"10.3171\/jns.1991.74.6.0861","article-title":"Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone","volume":"74","author":"Grunberg","year":"1991","journal-title":"J Neurosurg"},{"issue":"5","key":"key\n\t\t\t\t20170511102401_NOU148C10","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/neuonc\/nor044","article-title":"Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma","volume":"13","author":"Johnson","year":"2011","journal-title":"Neuro Oncol"},{"issue":"2","key":"key\n\t\t\t\t20170511102401_NOU148C11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00006123-199702000-00007","article-title":"The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B","volume":"40","author":"Kaba","year":"1997","journal-title":"Neurosurgery"},{"issue":"1","key":"key\n\t\t\t\t20170511102401_NOU148C12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11060-012-0861-0","article-title":"Bevacizumab therapy for adults with recurrent\/progressive meningioma: a retrospective series","volume":"109","author":"Lou","year":"2012","journal-title":"J Neurooncol"},{"issue":"3","key":"key\n\t\t\t\t20170511102401_NOU148C13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0090-3019(85)90030-8","article-title":"Antiestrogenic therapy of meningiomas\u2014a pilot study","volume":"24","author":"Markwalder","year":"1985","journal-title":"Surg Neurol"},{"issue":"1","key":"key\n\t\t\t\t20170511102401_NOU148C14","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11060-012-0886-4","article-title":"Atypical and anaplastic meningiomas treated with bevacizumab","volume":"109","author":"Nayak","year":"2012","journal-title":"J Neurooncol"},{"issue":"3","key":"key\n\t\t\t\t20170511102401_NOU148C15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11910-009-0034-5","article-title":"Advances in meningioma therapy","volume":"9","author":"Norden","year":"2009","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"2","key":"key\n\t\t\t\t20170511102401_NOU148C16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-009-9948-7","article-title":"Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma","volume":"96","author":"Norden","year":"2010","journal-title":"J Neurooncol"},{"issue":"1","key":"key\n\t\t\t\t20170511102401_NOU148C17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/neuonc\/nop017","article-title":"A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas","volume":"12","author":"Raizer","year":"2010","journal-title":"Neuro Oncol"},{"issue":"2","key":"key\n\t\t\t\t20170511102401_NOU148C18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-011-0687-1","article-title":"Phase II study of Gleevec(R) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma","volume":"106","author":"Reardon","year":"2012","journal-title":"J Neurooncol"},{"issue":"6","key":"key\n\t\t\t\t20170511102401_NOU148C19","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1215\/15228517-2009-010","article-title":"Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01\u201308)","volume":"11","author":"Wen","year":"2009","journal-title":"Neuro Oncol"},{"issue":"5","key":"key\n\t\t\t\t20170511102401_NOU148C20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1535-6108(03)00089-8","article-title":"PDGF receptors as cancer drug targets","volume":"3","author":"Pietras","year":"2003","journal-title":"Cancer Cell"},{"issue":"3","key":"key\n\t\t\t\t20170511102401_NOU148C21","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3171\/jns.1994.81.3.0388","article-title":"Platelet-derived growth factor expression and stimulation in human meningiomas","volume":"81","author":"Black","year":"1994","journal-title":"J Neurosurg"},{"issue":"1","key":"key\n\t\t\t\t20170511102401_NOU148C22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ijc.2910460106","article-title":"Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products","volume":"46","author":"Maxwell","year":"1990","journal-title":"Int J Cancer"},{"issue":"1","key":"key\n\t\t\t\t20170511102401_NOU148C23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02478918","article-title":"Different distribution of c-myc and MIB-1 positive cells in malignant meningiomas with reference to TGFs, PDGF, and PgR expression","volume":"18","author":"Nagashima","year":"2001","journal-title":"Brain Tumor Pathol"},{"issue":"5","key":"key\n\t\t\t\t20170511102401_NOU148C24","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ijc.2910460504","article-title":"Expression of PDGF beta-receptors in human meningioma cells","volume":"46","author":"Wang","year":"1990","journal-title":"Int J Cancer"},{"issue":"Suppl 1","key":"key\n\t\t\t\t20170511102401_NOU148C25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1054\/jocn.2001.0877","article-title":"Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas","volume":"8","author":"Yang","year":"2001","journal-title":"J Clin Neurosci"},{"issue":"2","key":"key\n\t\t\t\t20170511102401_NOU148C26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3171\/jns.2001.94.2.0293","article-title":"Evidence for mitogen-associated protein kinase activation and transduction of mitogenic signals by platelet-derived growth factor in human meningioma cells","volume":"94","author":"Johnson","year":"2001","journal-title":"J Neurosurg"},{"issue":"5","key":"key\n\t\t\t\t20170511102401_NOU148C27","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3171\/jns.1996.84.5.0852","article-title":"Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor","volume":"84","author":"Todo","year":"1996","journal-title":"J Neurosurg"},{"issue":"1\u20132","key":"key\n\t\t\t\t20170511102401_NOU148C28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1006416003964","article-title":"VEGF in brain tumors","volume":"50","author":"Machein","year":"2000","journal-title":"J Neurooncol"},{"issue":"2","key":"key\n\t\t\t\t20170511102401_NOU148C29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10014-010-0012-2","article-title":"Angiogenesis in meningiomas","volume":"28","author":"Barresi","year":"2011","journal-title":"Brain Tumor Pathol"},{"issue":"28","key":"key\n\t\t\t\t20170511102401_NOU148C30","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"key\n\t\t\t\t20170511102401_NOU148C31","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"key\n\t\t\t\t20170511102401_NOU148C32","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"7","key":"key\n\t\t\t\t20170511102401_NOU148C33","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol"},{"issue":"2","key":"key\n\t\t\t\t20170511102401_NOU148C34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/ng.2522","article-title":"Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors","volume":"45","author":"Chmielecki","year":"2013","journal-title":"Nat Genet"},{"issue":"2","key":"key\n\t\t\t\t20170511102401_NOU148C35","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng.2509","article-title":"Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat Genet"},{"issue":"5","key":"key\n\t\t\t\t20170511102401_NOU148C36","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00401-013-1117-6","article-title":"Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein","volume":"125","author":"Schweizer","year":"2013","journal-title":"Acta Neuropathol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/17\/1\/116\/12804103\/nou148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T21:07:38Z","timestamp":1649884058000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-lookup\/doi\/10.1093\/neuonc\/nou148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,6]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,8,6]]},"published-print":{"date-parts":[[2015,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/nou148","relation":{},"ISSN":["1523-5866","1522-8517"],"issn-type":[{"value":"1523-5866","type":"electronic"},{"value":"1522-8517","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8,6]]}}}